Drugs / Neo-DCVac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06675201 | Oct 2024 → Oct 2027 expected | esophageal squamous cell carcinoma | Sichuan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neo-DCVac | “personalized neoantigen dendritic cell vaccine (Neo-DCVac) combined with camrelizumab” PMID 41601631 ↗ Jan 2026 |
| Modality | Vaccine | “neoantigen-loaded dendritic cell vaccine” NCT06675201 ↗ |
| Route | Subcutaneous | “Neo-DCVac (0.5-2 × 107 cells per dose, subcutaneously, following cyclophosphamide pretreatment)” PMID 41601631 ↗ Jan 2026 |